Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086111 | 0.86 | SLC5A2 (0.36) | PREPSLC5A2CA12CA1CA9 | |
| SCHEMBL10135674 | 0.79 | SLC5A2 (0.48) | SLC5A2ALDH1A1LMNAHPGDPOLB | |
| SCHEMBL3773672 | 0.77 | PREP (0.42) | PREPSLC5A2CA12CA1CA9 | |
| SCHEMBL26988111 | 0.75 | PREP (0.46) | PREPCA12CA1CA9 | |
| SCHEMBL469663 | 0.75 | SLC5A2 (0.36) | SLC5A2 | |
| SCHEMBL462800 | 0.74 | SLC5A2 (0.37) | PREPSLC5A2CA12CA1CA9 | |
| SCHEMBL16871894 | 0.74 | PREP (0.39) | PREPSLC5A2CA12CA1CA9 | |
| SCHEMBL14478161 | 0.74 | PREP (0.44) | PREPCA12CA1CA9 | |
| SCHEMBL1457146 | 0.73 | PREP (0.40) | PREPSLC5A2CA12CA1CA9 | |
| SCHEMBL461010 | 0.72 | SLC5A2 (0.47) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | PREP 1772/4885SLC5A2 1/4885CA12 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.